08:00 – Abertura

Coordenação: Fabio Mansani e Felipe Zerwes (chat)

08:05 – 08:20
- Global Perspectives on Breast Cancer Care during the COVID-19 Pandemic how BC was managed and lessons Learned
Palestrante: Felipe Andrade

08:20 – 08:35
- De-escalation of Surgical Therapy: What Does the Data Support (DCIS Exceptional responders to neoadjuvant chemotherapy)
- GS2-02. 12 years results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ
Palestrante: Luiz Henrique Gebrim

08:35 – 08:50
- GS1-01. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
- GS1-02. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
- GS1-04. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies
Palestrante: Tomás Reinert

08:50 – 09:10
Henrique Lima Couto
Adriana Magalhães Freitas

Coordenação: Felipe Zerwes e André Mattar (chat)

09:10 – 09:20
- GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 years results
- GS2-04. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
Palestrante: Nilceana Freitas

09:20 – 09:30
- Preventing breast cancer through energy balance interventions
- Novel cancer prevention interventions
Palestrante: Sandra Gioia

09:30 – 09:45
- GS2-06. Exploring the causal role of the Human Gut Microbiome in Breast Cancer Risk using Mendelian Randomization
- GS2-07. Glycemic Index, Glycemic Load and breast cancer risk: results from the prospective NutriNet-Santé cohort

- GS2-09. Diabetes risk reduction diet and survival following breast cancer
Palestrante: Daniel Buttros

09:45 – 10:00
- Chronic stress, sleep deprivation and health implications on breast cancer survivors
- CVAs, infertility and gynecologic complications: what else is affecting the patient?
- Quality of life and support in breast cancer care
Palestrante: Rosemar Rahal

10:00 – 10:20
Annamaria Massahud
Iris Rabinovich

INTERVALO  10:20 – 10:30

Coordenação: André Mattar e Fabio Mansani (chat)

10:30 – 10:40
- GS4-04. Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: First efficacy results from the ADAPT HR+/HER2- trial (n=4,690)
- GS4-05. Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Palestrante: Daniel Argolo

10:40 – 10:50
- Advances in the Treatment of HER2+ Disease
- De-escalating therapy in early and late stage disease, and continuing antibody therapy post progression
Palestrante: Elge Werneck

10:50 – 11:00
- All Breast Cancer Patients Should Have Germline Genetic Testing
Palestrante: Patricia Prolla

11:00 – 11:20
Carlos Barrios
Franklin Pimentel

Coordenação: Fabio Mansani e Felipe Zerwes (chat)

11:20 – 11:30
- GS4-07. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore
- GS3-09. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis
Palestrante: Carlos Ruiz

11:30 – 11:45
- Management of the axilla in early stage disease
- Management of the clinically node positive axilla
- Refining the role of regional nodal irradiation
Palestrante: Antônio Frasson

11:45 – 12:00
- GS4-09. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study
- GS4-10. Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
- GS4-11. How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
Palestrante: Débora Gagliato

12:00 – 12:20
Francisco Pimentel
Darley Ferreira



Conheça nosso time.

Fale Conosco